JOURNAL OF THORACIC ONCOLOGY, vol.16, no.8, pp.1369-1378, 2021 (Journal Indexed in SCI)
Article / Article
Title of Journal :
JOURNAL OF THORACIC ONCOLOGY
Avelumab, PD-L1, Non-small cell lung cancer, Second-line, Phase 3, OPEN-LABEL, NIVOLUMAB, MULTICENTER
Introduction: In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.